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The striatum and the nucleus accumbens are the main input structures of the basal ganglia (BG). They contribute differently to motor behavior controlled by the BG in rats, e.g., stereotyped behavior, catalepsy, and locomotion.
Whereas the striaturn is predominantly involved in the control of sniffing behavior and catalepsy, the nucleus accumbens contributes to control of locomotion.
To test whether the allosteric glycine site of the NMDA receptor complex modulates these behavioral variables, we injected the glycine-site antagonist 7-chlorokynurenate and the glycine-site agonist o-serine into the anterodorsal striatum and the nucleus accumbens and studied their influence on stereotypical snout contacts and locomotion. Additionally, the effects of intrastriatal injections of 7-chlorokynurenate on haloperidoland SCH 23390-induced catalepsy were investigated. 7-Chlorokynurenate enhanced stereotypical snout contacts in the anterodorsal striatum and in the nucleus accumbens but did not change spontaneous locomotion in either of these structures.
Haloperidolbut not SCH 23390-induced catalepsy was attenuated by intrastriatally administered 7-chlorokynurenate.
The glycine-site agonist c-serine had no effect on stereotypical snout contacts and locomotion. The results suggest that motor behavior mediated by the striatopallidal output pathway is modulated by the glycine site, whereas motor behavior mediated by the accumbopallidal and striatonigral output pathway is not.
Key words: stereotypy; locomotion: striatum; nucleus accumbens; NMDA; glycine; 7-chlorokynurenate; o-serine Motor behavior is initiated, modulated, and controlled by parallel and functionally distinct loops coming from the cortex, passing the basal ganglia (BG), and reentering the cortex (Alexander et al., 1986; Alexander and Crutcher, 1990) . The striatum and the nucleus accumbens are the main input structures of the sensorimotorand limbicmotor-related loops, respectively. The structures receive glutamatergic input from the cortex and dopaminergic input from the midbrain. The dopamine-glutamate balance in the striatum and the nucleus accumbens contributes to motor behavior in the following ways.
In the anterodorsal striatum, local stimulation of the dopaminergic system (Staton and Solomon, 1984; Swerdlow and Koob, 1987) , inhibition of the glutamatergic system via blockade of NMDA receptors, and disruption of the corticostriatal efferents mainly stimulate stereotyped behavior, such as sniffing and repetitive head movement (Scatton et al., 1982; Schmidt, 1986; Imperato et al., 1990; Pierce and Rebec, 1993) . This behavior is enhanced by disruption of the corticostriatal efferents (Iversen et al., 1971) . In contrast, blockade of the dopaminergic system induces catalepsy with rigidity and akinesia (Ellenbroek et al., 1985; Ossowska et al., 1990; Yoshida et al., 1994) . These symptoms are antagonized by locally applied NMDA receptor antagonists, ablation of the frontal cortex, or quinolinic acid lesion of the striaturn (Calderon et al., 1988; Yoshida et al., 1991; Hauber and Schmidt, 1993) . However, local stimulation of the NMDA receptor reduces behavioral activity (Schmidt and Bury, 1988; Klockgether and Turski, 1993) and restores catalepsy in decorticated rats pretreated with a dopamine receptor antagonist (Yoshida et al., 1991) . In the nucleus accumbens, activation of the dopaminergic system, inhibition of the glutamatergic system, and neurotoxic lesion mainly stimulate locomotion (Donzanti and Uretsky, 1984; Staton and Solomon, 1984; Raffa et al., 1989; Imperato et al., 1990; Kelley and Throne, 1992; Weissenborn and Winn, 1992) . Blockade of dopamine receptors by antagonists reduces locomotor behavior (Meyer, 1993) whereas activation of NMDA receptors induces controversial results: sedation, locomotion, or no effects (Donzanti and Uretsky, 1984; Imperato et al., 1990) . Thus, it seems that the dopamine-glutamate balance in the striatum is involved mainly in the control of sniffing behavior, repetitive head movement, and catalepsy, whereas the balance in the nucleus accumbens is involved mainly in the control of locomotion. However, this "anatomofunctional" dichotomy has been discussed controversially in the past (LeMoal and Simon, 1991) . The glutamatergic system is positively modulated by a glycine site, which is located in the NMDA receptor complex next to the competitive, noncompetitive, and other binding sites (Wroblewski and Danysz, 1989) . Recent studies showed that blockade of the glycine site enhances stereotyped behavior, has no effect on locomotion, and reduces catalepsy in dopamine D2 receptor antagonist-pretreated rats or monoamine-depleted rats when it is injected into the third ventricle (Koek and Colpaert, 1990; Kretschmer et al., 1994 Kretschmer et al., , 1995 . However, systemically or intraventricularly given glycine-site antagonists are unable to attenuate dopamine Dl receptor antagonist-induced catalepsy (Kretschmer, 1994; Kretschmer et al., 1994) . A glycine-site agonist, o-cycloserine , potentiates  motor  behavior  mediated  by a noncompetitive  NMDA   receptor  antagonist  and antagonizes  motor  behavior  mediated  by a  competitive  NMDA  receptor antagonist, but has no effect on motor behavior by itself when it is systemically given (Kretschmer et al., 1992) . (Schmidt, 1986) . Catalepsy was quantified in three tests in the following order of succession:
(1) placing both forepaws of the rat on a horizontal bar 9 cm above the floor; (2) placing one forepaw of the rat on a podium (3 cm high); and (3) hanging the rat with all paws on a vertical grid.
The 7-Chlorokynurenate injected into the anterodorsal striatum enhanced in a dose-dependent manner the number of snout contacts in the sniffing box (Fig. 3A) (F(,,,,) = 6.2662; p < 0.0001). Also, AP-5 increased the number of snout contacts when it was injected into the anterodorsal striatum ( The number of line crossings was not enhanced by 7-chlorokynurenate (Fig. 4) (Fc5,051 = 2.5775;~ = 0.0354, relevant groups not significant in post hoc test).
Effects of 7-chlorokynurenate on haloperidolor SCH 23390-pretreated rats in the catalepsy test after injection into the anterodorsal striatum. Intrastriatally given 7chlorokynurenate reduced the catalepsy induced by haloperidol pretreatment at all three doses (5, 10, and 20 nmol) at the horizontal bar (Z0+'~3,57) = 14.488;~ = 0.0023). At the podium, only the highest dose (20 nmol) of 7-chlorokynurenate was effective (KW~3,57) = 7.819; p = 0.0499). At the vertical grid, only 10 nmol of 7-chlorokynurenate reduced the descent latency in haloperidol-pretreated rats (Fig. 5)  (m(3,57) = 12.561, p = 0.0057). However, the anticataleptic effects of 7-chlorokynurenate were very short-lasting (5-15 min). 7Chlorokynurenate (10 and 20 nmol) had no effect on SCH 23390-pretreated rats in all three catalepsy tests ( (Table 1) . We did not observe convulsions in any of the rats. 7-Chlorokynurenate increased the number of snout contacts in the sniffing box when it was injected into the nucleus accumbens mi5 7) (F(S,,") = 9.0443; p < 0.0001). However, intra-accumbal injection of 7-chlorolqnurenate did not enhance the number of line crossings (F(,,,,) = 2.225; p = 0.0648) as it was observed with AP-5 (Fig. 8A ,B) (t = 2.423, p = 0.0307). Injection of 7-chlorolqnurenate 90 set before testing did not modulate the number of snout contacts (t = 1.9,~ = 0.0732) and line crossings (t = 1.7,~ = 0.1071) ( Table 2) . NMDA also had no effect on the number of line crossings in the open field (t = 0.04871;~ = 0.9614) (Table 3 ), but it enhanced the time of inactivity (data not shown). No convulsions were observed in D-serine-or NMDA-treated rats.
DlSCUSSlON
The present study shows that stereotypical snout contacts, but not spontaneous locomotor behavior, are modulated by a glycine-site antagonist, whereas an NMDA receptor antagonist modulates both behavioral parameters. Furthermore, blockade of the glycine site can reduce catalepsy in rats pretreated with a dopamine D2 receptor antagonist, but not in rats pretreated with a dopamine Dl receptor antagonist. Stimulation of the glycine site has no effect on motor behavior, whereas NMDA itself reduces snout contacts in the striatum. In the past, the effects of NMDA receptor agonists were controversially discussed. Although some groups found that NMDA reduces motor behavior when given into the striatum or nucleus accumbens (Schmidt and Bury, 1988; Klockgether and Turski, 1993; Svensson et al., 1994) , others found that NMDA enhances motor activity or has no effect (Donzanti and Uretsky, 1984; Raffa et al., 1989; Imperato et al., 1990; Yoshida et al., 1991; Svensson et al., 1994) . Different doses and a toxic mechanism of NMDA may explain these heterogeneous results. In this respect, it has been shown that high doses of NMDA enhance dopamine release in a TTX-insensitive manner and that the induced locomotion is accompanied by convulsions, whereas lower doses are ineffective in influencing these parameters (O'Neill et al., 1989; Imperato et al., 1990; Wedzony et al., 1991; Svensson et al., 1994) . Glycine-site agonists are devoid of toxic actions but are also devoid of effects on sniffing behavior and spontaneous locomotion. However, they enhance the effects of noncompetitive NMDA receptor antagonists and reduce the effects of competitive NMDA receptor antagonists (Kretschmer et al., 1992) . Thus, the glycine site of the NMDA receptor complex meets its regulatory and modulatory function and becomes important if transmitter balances are changed.
The effects of the glycine-site antagonist 7-chlorokynurenate in the striatum and nucleus accumbens correspond to earlier findings showing that intraventricular or systemic injections of glycinesite antagonists enhance stereotypical snout contacts, have no effect on locomotion, and reduce dopamine D2 receptor-but not Dl receptor-mediated catalepsy (Koek and Colpaert, 1990; Hutson et al., 1991; Bristow et al., 1993; Kretschmer, 1994; Kretschmer et al., 1994 Kretschmer et al., , 1995 . Furthermore, the finding that the glycine-site antagonist more effectively induces stereotypical snout contacts when injected in the anterodorsal striatum than in the nucleus accumbens supports the notion that these two structures may contribute differentially to motor behavior. However, the effects are only moderate.
The suggestion of the functional dichotomy has been derived from earlier behavioral findings showing that activation of the dopaminergic system and blockade of NMDA receptors also have a greater influence on sniffing behavior in the striatum and a greater influence on locomotor behavior in the nucleus accumbens (Creese and Iversen, 1975; Kelly et al., 1975 Time until active movement on one paw was measured (descent latency) at horizontal bar (bau),podi.um, and vertical grid (grid). Mean t SEM are presented. SCH (0.5 mgikg, i.p.) n = 17; SCH + 7-CLKYN (10 nmol) IZ = 9; SCH + 7-CLKYN (20 nmol) it = 6. Data were analyzed by Kruskal-Wallis test followed by Mann-Whitney I/ test. 1992). In addition, anatomical findings may support the idea, indicating that the termination areas of the sensorimotor-related projections from the striatum and the limbicmotor-related projections from the nucleus accumbens terminate in two distinct parts of substantia nigra pars reticulata (SNr) and thalamus: for the striatum, in ventromedial and ventrolateral parts, and for the nucleus accumbens, in dorsomedial parts of the respective structures (Ricardo, 1980; Graybiel, 1984; Berendse et al., 1992; Haber et al., 1993; Lynd-Balta and Haber, 1994) . Assuming that this functional dichotomy is correct [which is not completely supported by the present results and has been discussed controversially in the past (LeMoal and Simon, 1991)], it is interesting that stereotypical snout contacts are also obtained by blockade of accumbal glycine sites.
A tentative explanation for this effect may be that glycine-site antagonists may enhance stereotypical snout contacts via a direct link of the sensorimotor-related and the limbicmotor-related loop. This link is given by afferents from the nucleus accumbens reaching not only the SNr and the ventral pallidum (VP), but also the substantia nigra pars compacta (Pennartz et al., 1994) . They 
Figure 7. Effects of 2.5-10 nmol of 7-chlorokynurenate (7.CLKYN) on stereotypical snout contacts in the nucleus accumbens. For clarity, data are presented as differences from control mean i SEM. Means of raw data are: vehicle/7-CLKYN (2.5 nmol) 156.2 5 10.41158.7 + 20.6 snout contacts per 5 min (n = 10110); vehicle/7-CLKYN (5 nmol) 196.1 2 9.91270 2 25.5 snout contacts per 5 min (n = 10111); vehicle/7-CLKYN (10 nmol) 137.7 i 11.71178.3 -t 11.3 snout contacts per 5 min (n = 14116). For statistical evaluation, raw data were analyzed by one-way ANOVA followed by Tukey's f test, '"p < 0.05 compared with vehicle-treated rats.
are GABAergic and terminate directly on the dopaminergic nigrostriatal neurons (Somogyi et al., 1981) , and may directly modulate the function of the sensorimotor-related loop. Nevertheless, a diffusion process of the glycine-site antagonist into the striatum cannot been excluded.
An alternative explanation for the enhanced stereotypical snout contacts after injection of 7-chlorokynurenate into the nucleus accumbens may be that a strict anatomical-functional dichotomy is not given for the behavioral effects of the glycine-site antagonist, although a different sensitivity of the glycine sites in the striatum and the nucleus accumbens exists.
The finding that the glycine-site antagonist 7-chlorokynurenate has no effect on spontaneous locomotion when injected into the nucleus accumbens or striatum was exciting because the present study shows that NMDA receptor heterogeneity can also have consequences on motor behavior.
The reason for this heterogeneity is unknown, but could be attributable to the heteromeric nature of the NMDA receptor complex: in vitro studies showed that an active NMDA receptor complex consists of two receptor subunits, an NMDARl subunit and one of four NMDAR2 (NMDAR2a-NMDAR2d) subunits. The four different NMDAR2 subunits have different affinities for glycine or glycine-site ligands. Thus, the pharmacological properties of the active NMDA receptor complex vary depending on the subunit assembly (Bigge, 1993; Seeburg, 1993) . This has been supported by binding studies, which suggest that in the striatum and the cortex, the NMDA receptor complex has a high affinity to glycine-site antagonists (Sakurai et al., 1993) . Therefore, glycine sites that have a low affinity for antagonists might be responsible for the inability of glycine-site antagonists to induce locomotion in the nucleus accumbens.
Catalepsy induced by dopamine D2 and Dl receptor antagonists is mediated by the striatum (Ellenbroek et al., 1985; Ossowska et al., 1990; Yoshida et al., 1991 Yoshida et al., , 1994 . Systemically and locally applied NMDA receptor antagonists and ablation of the frontal cortex reduce the cataleptic symptoms induced by dopamine D2 receptor antagonists because of the opposite action of dopamine at the D2 receptor and glutamate at the NMDA receptor in the striatum (Schmidt and Bubser, 1989; Yoshida et al., 1991 Yoshida et al., , 1994 Kretschmer et al., 1992) . Glycine-site antagonists also reduce the cataleptogenic actions of the dopamine D2 receptor antagonist haloperidol after systemic or intracerebroventricular (ICV) and, as shown here, local application into the striatum, as it was proposed (Kretschmer, 1994; Kretschmer et al., 1994) . However, it is amazing that systemically given NMDA receptor antagonists reduce dopamine Dl-mediated catalepsy (Schmidt et al., 1991; Verma and Kulkarni, 1992) , whereas intrastriatally (see above) and systemically or ICV-administered glycine-site antagonists fail to do so (Kretschmer, 1994; Kretschmer et al., 1994) .
One interpretation of the basis of functional anatomy may be that the striatum projects via two efferent pathways to lower BG nuclei [SNr and entopeduncular nucleus (EP)]: (1) via a direct striatonigral pathway; and (2) via an indirect pathway, passing the globus pallidus and the subthalamic nucleus. Dopamine Dl receptors are located mainly on the striatonigral pathway and excite the GABAergic efferents, whereas dopamine D2 receptors are located mainly on the indirect pathway and inhibit the GABAergic pathway (Gerfen et al., 1990) . A strict separation of dopamine Dl and D2 receptors has often been postulated, but an overlap of lo-50% has been found after mRNA or retrograde labeling, after c-fos expression, or after selective lesion of striatopallidal neurons (Gerfen et al., 1990; Harrison et al., 1992; Robertson et al., 1992; Surmeier et al., 1992) . Given that dopamine Dl and D2 receptors are distributed differently on the striatal efferents, the blockade of striatal dopamine D2 hyperactivity of the SNr and EP neurons via the indirect pathway by blocking the striatopallidal output. A glycine-site antagonist, acting as a functional NMDA receptor antagonist against dopamine D2 receptor mediated catalepsy, does not affect the cataleptic symptoms of a dopamine Dl receptor antagonist after intrastriatal application via this pathway. Thus, it seems unlikely that NMDA receptor antagonists have an important influence via the indirect pathway against Dl catalepsy. (2) Anatomical data show that NMDA receptors are located in the striatum as well as in lower BG (SNr and EP) (Albin et al., 1992) . Lesioning the SNr or EP with quinolinic acid antagonizes dopamine D2-and Dl receptor-mediated catalepsy (Zadow and Schmidt, 1994a,b) . Therefore, it seems be more likely that NMDA receptor antagonists, but not glycine-site antagonists, reduce dopamine Dlmediated catalepsy by blocking the SNr and EP neurons directly. It may be speculated that the NMDA receptor complex located in these structures also may have a low-affinity glycine site as it is proposed for accumbopallidal (nucleus accumens-VP) and accumbonigral (nucleus accumbens-SNr) efferents. It can be concluded that, in contrast to what we expected, the 15, 1996, 76(4) coupling of the glycine site to the NMDA receptor complex shows regional differences in the BG. A modulatory function of glycine sites on behavior mediated by the striatonigral output pathway of the sensorimotor-related loop and by the accumbopallidal output pathway of the limbicmotor-related loop seems unlikely with respect to the results of the present study. In contrast, behavior mediated by the striatopallidal loop of the sensorimotor-related pathway can be modulated by the allosteric glycine site of the NMDA receptor complex (Fig. 9 ).
